2 weeks Ago By ABMN Staff
Valuation and Earnings This table compares NovelStem International and its rivals gross revenue, earnings per share (EPS) and valuation. NovelStem International’s rivals have higher revenue and earnings than NovelStem International. NovelStem International is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk NovelStem International has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, NovelStem International’s rivals have a beta of 0.
82, meaning that their average share price is 18% less volatile than the S&P 500. Profitability Insider & Institutional Ownership 29.3% of shares of all “Retail stores, not elsewhere classified” companies are owned by institutional investors.
13.6% of NovelStem International shares are owned by company insiders. Comparatively, 16.
9% of shares of all “Retail stores, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Summary NovelStem International rivals beat NovelStem International on 8 of the 9 factors compared.
About NovelStem International ( Get Free Report ) NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp.
and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp.
was incorporated in 1993 and is headquartered in Boca Raton, Florida. Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter .
.
